Cancer Drug Discovery
MIMETAS offers advanced 3D tumor models that capture essential features of the tumor microenvironment. Our platform enables the assessment of therapeutic responses to (immuno)therapies with greater confidence and relevance, accelerating drug discovery.
Modeling the Tumor Microenvironment
The tumor microenvironment remains a major limitation in predictive drug testing, especially when assessing compound efficacy early in development. MIMETAS addresses this blind spot by integrating key components into a single perfused system.
- Tumor cells derived from diverse patient sources
- Perfused vasculature
- Tumor-associated fibroblasts
- Tumor-associated macrophages
- Infitrating lymphocytes
Triaging of compounds in a comprehensive tumor microenvironment provides critical insights in how compounds would behave in vivo and reduce risk of late stage failure.
Assays That Cover a Broad Range of Oncological Processes
We empower oncology researchers with fit-for-purpose, robust assays that reveal deeper biological mechanisms and support better clinical translation.
Explore some of our example applications below.
Immune Cell Migration
.avif)
CAR-T Efficacy in Solid Tumors
Tumor-Stroma- Macrophage Interaction
Combination Therapy Screening on HCC
Anti-Angiogenic Drug Discovery
.png)
Custom Tumor Sourcing
MIMETAS works has broad sourcing, isolation and banking capabilities. We can source specific tumors with limited annotation and can provide pathology and sequencing services (via selected partners).
